Korean Journal of Plant Resources (한국자원식물학회지)

The Plant Resources Society of Korea (한국자원식물학회)
권호 표지
DOI QR코드

DOI QR Code

The Improving Effect of Paeoniae Radix on Dextran Sulfate Sodium-induced Colitis in Mice

Dextran Sulfate Sodium으로 유도된 궤양성 대장염에 대한 작약의 개선 효과

  • Myung, Noh Yil (Department of Oriental Medicine and Healthcare, Wonkwang Digital University)
  • 명노일 (원광디지털대학교 한방건강학과)
  • Received : 2018.01.31
  • Accepted : 2018.06.11
  • Published : 2018.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Paeoniae Radix has been used as a traditional medicine for various diseases including hepatic disease. However, the inhibitory effect of Paeoniae Radix on intestinal inflammation has not been fully understood yet. The aim of this study was to evaluate the effect of Paeoniae Radix on colitis induced by dextran sulfate sodium in mice. To investigate the protective effects of Paeoniae Radix, the colitis mice were induced by drinking water containing 5% dextran sulfate sodium for 7 days. Mice were randomized into groups receiving Paeoniae Radix (100 mg/kg), sulfasalazine (150 mg/kg) as a positive control, or water as a negative control. We evaluated the effects of Paeoniae Radix on clinical signs induced by dextran sulfate sodium, measuring weight loss, colon length, and disease activity index. Additionally, to find a possible explanation for the anti-inflammatory effects of Paeoniae Radix, we evaluated the effects of Paeoniae Radix on the interleukin-6 and cyclooxygenase-2 levels in colitis tissue. The results indicated that mice treated with dextran sulfate sodium showed measurable clinical signs, including weight loss and reduced colon length. However, Paeoniae Radix treatment significantly improved the weight loss and disease activity index as clinical symptoms. Moreover, Paeoniae Radix inhibited the interleukin-6 and cyclooxygenase-2 expression levels in colon tissues treated with dextran sulfate sodium. Taken together, the findings of this study suggest that Paeoniae Radix may be useful for treating intestinal inflammation, including ulcerative colitis.

염증성 대장질환에 대한 작약의 효능 연구가 미비하여 본 연구에서는 dextran sulfate sodium로 유도된 궤양성 대장염의 임상증상인 체중감소, 결장단축, 질병활성화 정도에 대한 작약의 효과를 관찰하였다. 또한 대장 조직 내 염증매개인자인 interleukin-6 및 cyclooxygenase-2의 생성에 대한 작약의 효과를 측정하여 다음과 같은 결과를 얻었다. 첫째 dextran sulfate sodium로 유도된 궤양성 대장염에서 체중 감소에 대한 작약의 효과를 관찰한 결과 유의적으로 억제함을 확인하였다. 둘째 DSS로 유도된 궤양성 대장염에서 결장 단축에 대하여 작약의 억제 효과가 유의성 있게 나타났다. 셋째 dextran sulfate sodium로 유도된 궤양성 대장염에서 임상증상인 설사, 잠혈 및 출혈 등의 질병활성화 정도에 대한 작약의 효과를 관찰한 결과 유의적으로 질병활성화 정도를 억제하였다. 넷째 대장 조직내 염증매개인자인 interleukin-6 및 cyclooxygenase-2의 생성증가에 대한 작약의 억제효과를 확인 하였다. 본 연구는 작약의 효능을 과학적으로 입증한 결과로, 작약의 궤양성 대장염의 치료제 개발의 소재로서의 가능성을 시사한다.

Keywords

References

  1. Agoff, S.N., T.A. Brentnall, D.A. Crispin, S.L. Taylor, S. Raaka, R.C. Haggitt, M.W. Reed, I.A. Afonina, P.S. Rabinovitch, A.C. Stevens, Z. Feng and M.P. Bronner. 2000. The role of cyclooxygenase-2 in ulcerative colitis-associated neoplasia. Am. J. Pathol. 157(3):737-745. https://doi.org/10.1016/S0002-9440(10)64587-7
  2. Bae, K.H. 2003. Illustrated Book of Health for Longevity. Kyohaksa, Seoul, Korea. p. 426 (in Korean).
  3. Choi, C.H., Y.H. Kim, Y.S. Kim, B.D. Ye, K.M. Lee, B.I. Lee, S.A. Jung, W.H. Kim and H.Y. Lee. 2012. IBD study group of the Korean Association for the Study of Intestinal Diseases: Guidelines for the management of Ulcerative colitis. Korean J. Gastroenterol. 59(2):118-140. https://doi.org/10.4166/kjg.2012.59.2.118
  4. Chuang, W.C., W.C. Lin, S.J. Sheu, S.H. Chiou, H.C. Chang and Y.P. Chen. 1996. A comparative study on commercial samples of the roots of Paeonia vitchii and P. lactiflora. Planta. Med. 62(4):347-351. https://doi.org/10.1055/s-2006-957899
  5. Cooper, H.S., S.N. Murthy, R.S. Shah and D.J. Sedergran. 1993. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 69(2):238-249.
  6. Danese, S., M. Sans and C. Fiocchi. 2004. Inflammatory bowel disease: the role of environmental factors. Autoimmun. Rev. 3(5):394-400. https://doi.org/10.1016/j.autrev.2004.03.002
  7. Domenech, E. 2006. Inflammatory bowel disease: current therapeutic options. Digestion 73(1):67-76.
  8. Hendel, J. and O.H. Nielsen. 1997. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. Am. J. Gastroenterol. 92(7):1170-1173.
  9. Hendrickson, B.A., R. Gokhale and J.H. Cho. 2002. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin. Microbiol. Rev. 15(1):79-94. https://doi.org/10.1128/CMR.15.1.79-94.2002
  10. Hsieh, C.L., C.Y. Cheng, T.H. Tsai, I.H. Lin, C.H. Liu, S.Y. Chiang, J.G. Lin, C.J. Lao and N.Y. Tang. 2006. Paeonol reduced cerebral infarction involving the superoxide anion and microglia activation in ischemia-reperfusion injured rats. J. Ethnopharmacol. 106(2):208-211. https://doi.org/10.1016/j.jep.2005.12.027
  11. Hyams, J.S. 2000. Inflammatory bowel disease. Pediatr. Rev. 21(9):291-295. https://doi.org/10.1542/pir.21-9-291
  12. Ishiguro, K., T. Ando, O. Maeda, M. Hasegawa, K. Kadomatsu, N. Ohmiya, Y. Niwa, R. Xavier and H. Goto. 2006. Paeonol attenuates TNBS-induced colitis by inhibiting NF-B and STAT1 transactivation. Toxicol. Appl. Pharmacol. 217(1): 35-42. https://doi.org/10.1016/j.taap.2006.07.002
  13. Ji, S.T., S.J. Lee, K.E. Lee, Y.T. Son and Y.K. Chung. 2002. Inhibitory effect of extracts from Paeoniae radixon Postprandial Hyperglycemia. J. Korean Soc. Food Sci. Nutr. 31(1):131-135. https://doi.org/10.3746/jkfn.2002.31.1.131
  14. Kawamori, T., C.V. Rao, K. Seibert and B.S. Reddy. 1998. Chemopreventive activity of elecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58: 409-412.
  15. Kim, J.H. and E.J. Kim. 2018. Evaluation of anti-oxidative, anti-thrombin, anti-invasive and pro-apoptotic activities of Paeonia japonica. Korean J. Plant Res. 31(1):16-23. https://doi.org/10.7732/KJPR.2018.31.1.016
  16. Lee, B., Y.W. Shin, E.A. Bae, S.J. Han, J.S. Kim, S.S. Kang and D.H. Kim. 2008. Antiallergic effect of the root of Paeonia lactiflora and its constituents paeoniflorin and paeonol. Arch. Pharm. Res. 31(4):445-450. https://doi.org/10.1007/s12272-001-1177-6
  17. Li, Y., C. de Haar, M. Chen, J. Deuring, M.M. Gerrits, R. Smits, B. Xia, E.J. Kuipers and C.J. van der Woude. 2010. Diseaserelated expression of the IL-6/STAT3/SOCS3 signaling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 59(2):227-235. https://doi.org/10.1136/gut.2009.184176
  18. Lichtenstein, G.R. and P. Rutgeerts. 2010. Importance of mucosal healing in ulcerative colitis. Inflamm. Bowel. Dis. 16(2):338-346. https://doi.org/10.1002/ibd.20997
  19. Lim, K.S., J.K. Park, M.H. Jeong, I.H. Bae, D.S. Park, J.W. Shim, J.H. Kim, H.K. Kim, S.S. Kim, D.S. Sim, Y.J. Hong, J.H. Kim and Y. Ahn. 2018. Anti-inflammatory effect of gallic acid-eluting stent in a Porcine Coronary Restenosis Model. Acta. Cardiol. Sin. 34(3):224-232.
  20. Lyu, Z.K., C.L. Li, Y. Jin, Y.Z. Liu, X. Zhang, F. Zhang, L.N. Ning, E.S. Liang, M. Ma, W. Gao, M.X. Zhang and D.S. Liu. 2017. Paeonol exerts potential activities to inhibit the growth, migration and invasion of human gastric cancer BGC823 cells via downregulating MMP 2 and MMP 9. Mol. Med. Rep. 16(5):7513-7519.
  21. Matuk, R., J. Crawford, M.T. Abreu, S.R. Targan, E.A. Vasiliauskas and K.A. Papadakis. 2004. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 10(4):352-356. https://doi.org/10.1097/00054725-200407000-00005
  22. Ministry of Food and Drug Safety. 2014. Korean Pharmacopeia (tenth edition) Monographs Part2. Ministry of Food and Drug Safety, Cheongju, Korea. p. 1341.
  23. Murthy, S.N., H.S. Cooper, H. Shim, R.S. Shah, S.A. Ibrahim and D.J. Sedergran. 1993. Treatment of dextran sulfate sodium-induced murine colitis by intracoloniccyclosporin. Dig. Dis. Sci. 38(9):1722-1734. https://doi.org/10.1007/BF01303184
  24. Ngan, L.T., M.J. Jang, M.J. Kwon and Y.J. Ahn. 2015. Antiviral activity and possible mechanism of action of constituents identified in Paeonia lactiflora root toward human rhinoviruses. PLoS One 10(4):e0121629.
  25. Ogata, H. and T. Hibi. 2003. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr. Pharm. Des. 9(14): 1107-1113. https://doi.org/10.2174/1381612033455035
  26. Oriental Medicine Pharmacology Textbook Compilation Committee. 2010. Oriental Medicine Pharmacology (third edition). Shinilbooks, Seoul, Korea. pp. 694-700 (in Korean).
  27. Papadakis, K.A. and S.R. Targan. 2000. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu. Rev. Med. 51:289-298.
  28. Park, K.K., H.S. Park, Y.H. Cho, H.O. Yang, W.K. Ko, H.S. Ro and Y.E. Lee. 1999. Isolation of hyperlipidemic substancesfrom methanol extract of Paeoniae radix. J. Pharm. Investig. 29: 55-60.
  29. Ro, H.S., W.K. Ko, H.O. Yang, K.K. Park, Y.H. Cho and H.S. Park. 1997. Effect of several solvent extracts from Paeoniae radix on experimental hyperlipidemia in rats. J. Pharm. Investig. 27:145-151.
  30. Roberts, P.J., K. Morgan, R. Miller, J.O. Hunter and S.J. Middleton. 2001. Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease. Gut 48(4):468-472.
  31. Rogler, G. and T. Andus. 1998. Cytokines in inflammatory bowel disease. World J. Surg. 22(4):382-389. https://doi.org/10.1007/s002689900401
  32. Tsai, H.Y., H.Y. Lin, Y.C. Fong, J.B. Wu, Y.F. Chen, M. Tsuzuki and C.H. Tang. 2008. Paeonol inhibits RANKLinduced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway. Eur. J. Pharmacol. 588(1):124-133. https://doi.org/10.1016/j.ejphar.2008.04.024
  33. Vazquez Cisneros, L.C., P. Lopez-Uriarte, A. Lopez-Espinoza, M. Navarro Meza, A.C. Espinoza-Gallardo and M.B. Guzman Aburto. 2017. Effects of green tea and its epigallocatechin (EGCG) content on body weight and fat mass in humans: a systematic review. Nutr. Hosp. 34(3):731-737.
  34. Wu, H.K. and S.J. Sheu. 1996. Capillary electrophoretic determination of the constituents of Paeoniae radix. J. Chromatogr. A. 753(1):139-146.
  35. Zhang, J., W. Dou, E. Zhang, A. Sun, L. Ding, X. Wei, G. Chou, S. Mani and Z. Wang. 2014. Paeoniflorin abrogates DSSinduced colitis via a TLR4-dependent pathway. Am. J. Physiol. Gastrointest. Liver Physiol. 306(1):G27-36.
  36. Zhong, S.Z., Q.H. Ge, R. Qu, Q. Li and S.P. Ma. 2009. Paeonol attenuates neurotoxicity and ameliorates cognitive impairment induced by d-galactose in ICR mice. J. Neurol. Sci. 277(1-2): 58-64. https://doi.org/10.1016/j.jns.2008.10.008